Register Now

Tatva Chintan Pharma shares in focus after CRISIL downgrades ratings on bank facilities

CRISIL highlighted that the revision in Tatva Chintan’s ratings and outlook is due to the moderation in the company’s business risk profile.

Leave a Reply

Your email address will not be published. Required fields are marked *